Companies run numerous disconnected AI pilots in R&D, commercial, and other silos, each with its own metrics. This fragmented approach prevents enterprise-wide impact and disconnects AI investment from C-suite goals like share price or revenue growth. The core problem is strategic, not technical.

Many firms are stuck in "pilot purgatory," launching numerous small, siloed AI tests. While individually successful, these experiments fail to integrate into the broader business system, creating an illusion of progress without delivering strategic, enterprise-level value.

To truly benefit from transformative AI, leaders are advised against running small, tactical pilots. Instead, they should develop a clear strategy, make a decisive commitment to a platform, and integrate it as a core strategic initiative. This approach avoids incrementalism and achieves significant results much faster.

Many firms engage in "innovation theatre," building a portfolio of impressive but isolated AI pilots. Without a unifying strategic architecture connecting them to core growth objectives, these initiatives remain islands that fail to scale, compound, or move overall enterprise performance.

Many pharma companies have breakthrough AI results in isolated functions, or "pockets of excellence." However, the ultimate competitive advantage will go to the company that first connects these disparate successes into a single, integrated, enterprise-wide AI capability, thereby creating compounded value across the organization.

Many companies fail at AI by cobbling together disparate tools without a coherent strategy. Successful "pacesetters" adopt a holistic, platform-first mindset, providing structure, expertise, and focusing on high-value projects enterprise-wide, which avoids this pitfall.

Leaders who say "we need an AI strategy" often reveal a lack of a clear core business strategy. AI should be a component that enables the overall company vision, not a separate initiative. This mindset shift grounds AI efforts in tangible business value tied to your unique differentiators.

Long-term competitive advantage will belong not to firms with the best algorithms, but to those that build the most intelligent organizations *around* AI. The key is developing the ability to absorb, direct, and compound AI's power in service of coherent strategic goals.

Pharma companies engaging in 'pilotitis'—running random, unscalable AI projects—are destined to fall behind. Sustainable competitive advantage comes from integrating AI across the entire value chain and connecting it to core business outcomes, not from isolated experiments.